Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy.
about
Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining ConditionsPrevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohortPolypharmacy in the HIV-infected older adult population.Potential drug-drug interactions in HIV-perinatally infected adolescents on antiretroviral therapy in Buenos Aires, Argentina.Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infectionClinically significant interactions between antiretroviral and co-prescribed drugs for HIV-infected children: profiling and comparison of two drug databases.Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management.Potential drug-drug interactions in HIV-infected children on antiretroviral therapy in Lagos, Nigeria.Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.Clinically significant drug interactions in younger and older human immunodeficiency virus-positive patients receiving antiretroviral therapy.Prevalence of drug interactions in hospital healthcare.Recognition of possible risk factors for clinically significant drug-drug interactions among Indian people living with HIV receiving highly active antiretroviral therapy and concomitant medications.Addressing Antiretroviral Therapy-Associated Drug-Drug Interactions in Patients Requiring Treatment for Opportunistic Infections in Low-Income and Resource-Limited Settings.Comparing the Frequencies of Contraindicated Drug-Drug Interactions Between Differing Antiretroviral Regimens in HIV-Infected Patients.Antiretroviral Treatment and Resistance Patterns in HIV-Infected Children.Associated factors of drug-drug interactions of highly active antiretroviral therapy: report from a referral center.Identification of potential clinically significant drug interactions in HIV-infected patients: a comprehensive therapeutic approach.A review of drug-drug interactions in older HIV-infected patients.Frequency of electrocardiogram testing among HIV-infected patients at risk for medication-induced QTc prolongation.Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients.Identification of potential drug-drug interactions between antiretroviral drugs from prescriptions in the private health-care sector in South Africa.Challenges in the treatment of chronic hepatitis C in the HIV/HCV-coinfected patient.Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients.Assessment of Drug-Drug Interaction in Ayder Comprehensive Specialized Hospital, Mekelle, Northern Ethiopia: A Retrospective Study.Frequency and severity of potential drug interactions in a cohort of HIV-infected patients Identified through a Multidisciplinary team.Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications.Incidence of Antiretroviral Drug Interactions During Hospital Course: The Role of a Pharmacist-Led Antiretroviral Stewardship Program.Prevalence and Predictors of Important Telaprevir Drug Interactions Among Patients Coinfected With Hepatitis C and Human Immunodeficiency Virus.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015
P2860
Q26740117-EF6A1BC9-2A24-4AB0-85F7-11ECB83E3D8BQ28477246-D5AC8F0A-475C-461A-84FF-1E320AA38808Q34037407-E86F2025-09D4-4D98-AB16-4CD3A77B010AQ34477120-A490F5D3-B1F5-43BD-966B-A2E9EC058E83Q36320042-BE71156C-AC8E-4376-8C7B-8CE2A1100472Q36863063-E824C8BC-4B0B-45C3-BF9B-A24679C1F205Q37378110-CEA4EB05-BCFA-437F-AD51-5F92EA3EED65Q37696834-C5B7AD5B-9C25-458F-9328-DFE9411DC831Q37850890-D2F6F5A1-6244-448F-A4F6-1EC4DC3F0AEFQ37933363-A7AF672D-2F4F-4062-A1F5-DC79A458D1A7Q38042334-5BF32746-CA40-4E39-A6DA-428263EA7CDCQ40051310-F6CC5151-00D5-4055-BBA7-E935A12B2126Q40051462-B2B0997D-A27A-4486-9B72-86077F39F943Q40262860-87471E48-A341-45C3-8B00-A89B263C5404Q41026791-F2F33B30-BB44-4142-B015-2144A0115740Q41564295-0BDCC2A6-5976-4CA1-99A5-74A3BCBA3EAEQ41591785-694809A2-4DC0-4378-BE22-E7BC36B85A91Q41996857-A06F20FB-6233-45C9-8DCB-0AF0A67960AEQ42990255-E37E3EF7-8702-4080-B713-0339503DD516Q43254867-DDC7CBFE-D6E5-4A2E-A54C-6CA775B3903BQ43790091-1B6BBCB7-C40A-4714-B1B1-C39BFBFE3A10Q44369266-9E299D31-E6E3-48E1-8165-534750655FBCQ46143194-C717CE29-ECF9-40ED-9FE7-F5330CB49FF5Q46314496-C07D9BC9-46A7-4F92-BB8D-084CFE8334EEQ47407447-D9CF696D-1104-42D7-A730-1EE287456FA1Q52312048-DFC19B32-D547-47D7-8939-19424EABAF20Q55186790-A74BF27A-C049-44E2-8D58-6086370A540CQ55284788-0834914F-8C99-480A-A5D9-14600676D350Q57180790-A8945E95-63FE-4883-93F3-5B5FB7555418
P2860
Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Prevalence and risk factors fo ...... s with antiretroviral therapy.
@en
type
label
Prevalence and risk factors fo ...... s with antiretroviral therapy.
@en
prefLabel
Prevalence and risk factors fo ...... s with antiretroviral therapy.
@en
P2093
P2860
P356
P1433
P1476
Prevalence and risk factors fo ...... s with antiretroviral therapy.
@en
P2093
Christopher D Miller
John J Faragon
Ramy El-Kholi
Thomas P Lodise
P2860
P304
P356
10.1592/PHCO.27.10.1379
P407
P577
2007-10-01T00:00:00Z